State of Art of the French Telemedicine Projects in the Field of Chronic Heart Failure

E Andres1,2∗, S Talha2,3, M Hajjam4 and A Hajjam5

1Department of Internal Medicine, Diabetes and Metabolic Diseases, Medical Clinic B, Strasbourg University Hospitals, Strasbourg, France
2Faculty of Medicine of Strasbourg, University of Strasbourg, Strasbourg, France
3Department of Physiology and Functional Explorations, Strasbourg University Hospitals, Strasbourg, France
4PREDIMED Technology, Strasbourg, France
5University of Technology Belfort-Montbéliard, Belfort-Montbéliard, France

∗Corresponding author: Prof. Emmanuel Andrès, Department of Internal Medicine, Diabetes and Metabolic Diseases, Medical Clinic B, Strasbourg University Hospitals, Strasbourg, France, Tel: 33388115066; E-mail: emmanuel.andres@chru-strasbourg.fr

Received date: April 25, 2018; Accepted date: May 11, 2018; Published date: May 18, 2018


Abstract

Background: This is a narrative short review of the literature pertaining to telemedicine projects developed in the field of chronic heart failure (CHF), with special attention to the French projects.

Results: Numerous telemedicine projects, based on connected objects or information and communication technology (ICT), have emerged over the last five years or are under development in the field of CHF. This is the case of the telemedicine projects: SCAD, OSCAT, PIMS, MEDICA and E-care. The E-care project is a French telemonitoring project of new generation. This project support patients returning home after hospital. It fits perfectly within the framework of telemedicine 2.0 projects, including for the first time artificial intelligence (AI). This project has been specifically designed to automatically detect situations at risk for CHF. The potential contribution of these French projects (OSCAT, E-care) is currently under study or documentation, especially in terms of mortality or morbidity, in addition to number of hospitalizations avoided, or economic benefits.

Keywords: Telemedicine; Artificial intelligence; Information and communication technology; Heart failure

Introduction

The rising prevalence of chronic disease like chronic heart failure (CHF) combined with population aging now represents a very real problem for public health [1]. In France, between 120 000 and 150 000 new cases are diagnosed every year [2]. The cost of this chronic disease has rocketed, and is estimated at several billion dollars in developed countries [1]. The management of CHF patients is a challenge for healthcare professionals. Their needs eat up large amounts of medical resources, just as a shortage in the time careers can provide is beginning to be felt, with medical deserts and a lack of access to healthcare professionals, among other problems.

CHF remains a serious disease in terms of their functional or survival prognosis, and morbidity and mortality are high [1]. Thus, the mortality rate of CHF patients with NYHA stage III-IV is 50% at 5 years (although closer to 30% in more recent studies) [2,3]. In this setting, CHF patients frequently present for emergency hospitalization and re-hospitalization [1,2]. CHF is responsible for more than 100 000 hospitalizations per year in France [2]. It accounts for 5% of all hospitalizations and is the main cause of hospitalization among elderly subjects [2]. Some of these hospitalizations could be avoided if patients have a better followed [1]. This last point has been particularly well documented in CHF [1,4]. In this setting, telemedicine may be of really aid. Indeed telemedicine may even optimize the management of such chronic disease, particularly by preventing emergency and repeat hospitalizations [2,4].

In this article we review the literature on French telemedicine projects developed in the area of CHF.

Search Strategy

A literature search was performed on the PubMed database of the US National Library of Medicine and on Scholar Google. We searched for articles published between January 2010 and April 2018, using the following key words or associations: “heart failure”, “telemedicine”, “e-Health”, “telemedicine in heart failure” and “e-Health in heart failure”; restrictions included: English- or French-language publications; published from January 1, 2010, to April 1, 2018; human subjects; clinical trials, review articles or guidelines. All of the English and
French abstracts were reviewed by at least two senior researchers from our work group. After rigorous selection, only 20 papers and fewer than 4 projects under study were selected and analyzed. The latter (references [4-35]) were used to write this paper in the form of a narrative short review. Information gleaned from international meetings was also used, as information gleaned from commercial sites on the web.

Results of Published Telemedicine Projects

General data on structured telephone support and first generation telemonitoring

Since the beginning of the 2000’s, numerous telemedicine projects have been conceived and developed in the area of CHF [6-22]. Practically, all of them have investigated “telemonitoring” (or tele management, as it is also known in the literature), as defined under French legislation [23]. To our knowledge, no completed projects have been published on “tele-consultation” and “tele-expertise” in the area of CHF. Some of the projects have very specifically investigated CHF subjects aged over 75 or over 80 [24,25]. It is worth bearing in mind that those projects, particularly the earlier ones, more closely resembled telephone follow-up with care providers (such as a nurse) traveling to the patient’s home, rather than telemedicine as we think of it nowadays with nonintrusive, automated, smart telemonitoring using remote sensors via modern communication technology or even artificial intelligence (AI) [4,21]. Hence in our opinion those studies represent the first generation of telemedicine projects [4,15].

Clinical impact of first generation telemedicine projects

As we will see, the results of telemedicine projects in the field of CHF differed from study to study and were fairly inconclusive regarding any potential clinical benefit in terms of, for instance, re-hospitalization or a decrease in morbidity and mortality (Table 1) [6-22]. This particularly applied to the statistical significance of the results. Because of this, the experts had divided opinions about the real utility of telemedicine in the management of CHF patients. Nevertheless, telemedicine is recommended with a low level of evidence for such patient follow-up by the European Society of Cardiology. In this setting, it should also be pointed out that the studies were conducted with sometimes inappropriate methodologies, in unsuitable patient groups (such as NYHA stage I) and, above all, in small patient samples (of between 50 and 1000 patients) with very short follow-up periods (of between 3 months and 1 year). In our opinion, this made any clinical benefit they demonstrated illusory [4,21]. Despite these limitations, several reviews and meta-analyses seem to have shown an undeniable utility for telemedicine [3,17].

Table 1: Potential studied parameters for impact documentation of telemedicine in chronic heart failure patient.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global mortality</td>
<td>Therapeutic education</td>
</tr>
<tr>
<td>Heart failure mortality</td>
<td>Hygiene-dietary and therapeutic observance</td>
</tr>
<tr>
<td>Hospitalization for heart failure</td>
<td>Optimization of food and sports hygiene</td>
</tr>
<tr>
<td>Iterative hospitalization for heart failure</td>
<td>Self-patient management</td>
</tr>
<tr>
<td>Number of hospitalization days</td>
<td>Optimization of the fitness trail</td>
</tr>
<tr>
<td>Health cost</td>
<td>Structuring of the fitness trail</td>
</tr>
<tr>
<td>Heart failure management cost</td>
<td>City-hospital relations</td>
</tr>
<tr>
<td>Number of days off work</td>
<td>Information sharing within health professional</td>
</tr>
<tr>
<td>Quality of life</td>
<td>System use by health professionals</td>
</tr>
</tbody>
</table>

For instance, Inglis, et al. [17] found that telemedicine had an effect on all-cause mortality, which fell significantly by 34% (p<0.0001). In that study, the authors also revealed that re-hospitalization for CHF fell by 20%, that the quality of life of patients and cost of management improved, and that the system was well accepted. In the meta-analysis by Anker et al. [4], 11 studies were analyzed as part of a comparison between the effects of telemonitoring and routine care (non-invasive telemedicine). Their research revealed that telemonitoring led to a reduction of all-cause mortality (10.4% vs. 15.4%; p < 0.0001), all-cause hospitalization (47.2% vs. 52.1%; p = 0.02), and hospitalization for CHF (22.4% vs. 28.5%; p = 0.008).

Conversely, two prospective clinical trials, the “gold standard”, have produced results that contradict the previous ones and question the potential utility of telemedicine in CHF [18,19]. The Tele-HF study randomized patients hospitalized for CHF to telemonitoring (n=826) or standard care (n=827) [18]. Patients were randomized to either voice-based interactive structured telephone support or usual care. Those in the intervention arm were advised to call a toll-free telephone system and answer a series of questions regarding their general health, weight, and HF symptoms on a daily basis. A clinician then analyzed the information. The study found no significant difference between the telemonitoring and standard management groups in terms of all-cause readmission or all-cause mortality in the 180 days after inclusion (odds ratio [OR]: 1.04 [CI95%: 0.91-1.19]). The primary outcome, all-cause readmission or death within 180 days after enrollment occurred in 52.3% of the telemonitoring group and 51.5% of the usual care group. However, there was poor adherence despite system generated reminders: 14% of patients in the telemonitoring arm of the study never used the system. By the final week, only 55% of the patients were using the system at least three times a week.
The TIM-HF study in Germany randomly compared two groups of patients with stable CHF, namely those followed by telemonitoring (n=354) and those receiving standard care (n=356) [19]. The TIM-HF trial studied 710 stable CHF patients randomized to either remote monitoring and telephone support or usual care. Patients were given a personal digital assistant (PDA) with a wireless Bluetooth interface. The system collected electrocardiogram data, blood pressure readings, and body weight; this information was then communicated wirelessly to a central location with physician presence 24 h a day, 7 days a week. In that study, the all-cause mortality rate was 8.4 per 100 patient-years of follow-up in the telemedicine group and 8.7 per 100 patient-years of follow-up in the standard care group (OR: 0.97 [CI95%: 0.67-1.41]; p=0.87). The TIM-HF trial was underpowered to detect a significant difference in mortality between the two groups. The composite secondary outcomes of hospitalization for HF and death due to a cardiovascular cause (14.7% vs. 16.5%) highlight the stable nature of the patients recruited in the study given population- and trial-based observations of readmission rates closer to 50%.

Financial impact of first generation telemedicine projects

Aside from these medical considerations, it is worth noting that all the studies seem to agree that using telemedicine solutions in the management of CHF was at least economically beneficial [Table 1] [6-21]. Depending on the study, the savings were calculated to be between $5,000 and more than $50,000/year/patient depending on the stage of CHF and the setting of the study. For instance, in the study by Scalveni et al. [22] the cost of managing CHF patients fell by 24%, and hospital costs fell by €45,186/patient/year.

In this setting, the study by Burdese et al. [25] is one of the most convincing for illustrating the utility of tele management in CHF elderly patients. In this study, a significant fall was observed in re-hospitalization (35 without vs. 12 with telemedicine, p = 0.0001), in visits to the emergency department for an acute episode of HF (21 vs. 5/y, p = 0.0001) and in the cost of management (€116,856 vs. €40,065/y). What’s interesting is that only 8.6% of the patients discontinued tele management, showing that it was well accepted.

Results of French Telemedicine Projects Currently Underway

General data

Over the last 4 to 5 years, a second generation of projects has emerged in the CHF area, particularly in France [21,26-31]. These projects are known as “telemedicine 2.0”, because they utilize the new “Information and Communication Technology” (ICT) and the web. They satisfy the conditions of telemedicine as laid out in France in Article 36 of the Social Security Financing Act [Table 1] [5]. Most of these projects rely on the usual connected tools for monitoring CHF, such as blood pressure meters, weighing scales, and pulse oximeters, which relay the information collected via Bluetooth, 3G or 4G and incorporate tools for interaction between the patient and healthcare professionals like telephone support centers, tablets, and websites [21]. Some of them also provide tools for motivation and education, and occasionally, questionnaires about symptoms, such as dyspnea, palpitation and edema as experienced by the patient.

The main new telemedicine projects currently being developed in France are:

- **SCAD**: “Suivi Cardiologique à Distance” [remote cardiological follow-up], first initiated in 2005, deployed in the low Normandie, France between 2009 April and May 2012, developed by Caen University Hospital [26].
- **PIMPS**: “Plateforme Interactive Médecins patients Santé” [doctor-patient interactive health platform], initiated in 2013, developed by René-Dubos hospital in Pontoise, France, and Professor Jourdain [27].
- **OSICAT**: “Optimisation de la Surveillance ambulatoire des Insuffisants Cardiaques par Télécardiologie” [optimization of outpatient monitoring in heart failure patients using telecardiology], initiated in 2012, involving 12 local investigation centers coordinated by Toulouse University Hospital and Professors Galinier and Pathak [28].
- **MEDICA**: “Monitorage Electronique à Domicile de l’Insuffisance Cardiaque chronique” [electronic home-monitoring of chronic heart failure], initiated in 2014, developed by the REUNICA domicile and GMC-solutions santé groups working in social protection of the elderly [29].
- **E-care**: “Détection des situations à risque de décompensation cardiaque chez les patients insuffisants cardiaques de stade III de la NYHA” [detection of risk situations for cardiac decompensation in heart failure patients with NYHA stage-III disease], initiated in 2014, the medical aspects of which were developed by Strasbourg University Hospital [30,31].

All these projects are run with the aid of the telemedicine 2.0 tools discussed above. The PIMPS project also comprises laboratory monitoring of natriuretic peptide [27]. These projects center on cohorts of CHF patients or prospective studies. They have enrolled relatively large patient samples, and most of them are based on data from evidence-based medicine. The OSICAT study seems the most advanced [28]. It was launched in 2013 and has enrolled 990 patients divided into two groups, remote home-monitoring and controls receiving standard care.

The results will include an assessment of medical efficacy and cost-effectiveness, and are expected in 2018. To our knowledge, only E-care project includes artificial intelligence tools [30,31]. The E-care telemonitoring project in Strasbourg falls under this category of telemedicine 2.0. It has been developed to optimize the home-monitoring of CHF patients. It detects situations in which there is a risk of cardiac decompensation and re-hospitalization, and it does this via a
telemonitoring 2.0 platform. The E-care platform automatically generates indicators of a worsening of the patient's health status. These "warning alerts" are generated for any decompensation of a chronic disease, particularly CHF, which may lead to hospitalization if not treated. To our knowledge, it is the first project that used artificial intelligence (AI) in addition to information and communication technologies. The platform includes connected nonintrusive medical sensors, a touchscreen tablet that is connected by Wi-Fi and a router or 3G/4G, making it possible to interact with the patient and provide education on treatment, diet and lifestyle (Figure 1).

The E-care system includes a server that hosts the patient's data and a secure Internet portal to which the various hospital- and non-hospital-based healthcare professionals can connect. E-care is based on a smart system comprising an inference engine and a medical ontology for personalized synchronous or asynchronous analysis of data specific to each patient and, if necessary, the sending of an alert generated by AI [32].

Between February 2014 and April 2015, 175 patients were given the chance to use the E-care platform [30]. During this period, the E-care platform was used on a daily basis by patients and healthcare professionals according to a defined protocol of use specific to each patient. The mean age of these patients was 72 years and the ratio of men to women was 0.7. The patients suffered from multiple concomitant diseases and had a mean Charlson index of 4.1. The five main diseases were: CHF in more than 60% of the subjects, anemia in more than 40%, atrial fibrillation in 30%, type II diabetes in 30%, and chronic obstructive pulmonary disease in 30%. During the study, 1,500 measurements were taken in these 175 patients, which resulted in the E-care system generating 700 alerts in 68 patients [33]. Some 107 subjects (61.1%) had no alerts during follow-up. Analysis of the follow-up of these 107 patients revealed that they had no clinically significant events that might eventually have led to hospitalization. Analysis of the warning alerts showed that the E-care platform automatically and non-intrusively detected any worsening of the patient's health, particularly CHF. Indeed, it was in this last setting that the system yielded the best sensitivity, specificity, and positive and negative predictive values, respectively 100%, 72%, 90% and 100%. The E-care platform also showed its ability to detect a deterioration in health status via the multiple diseases of the patients studied, with sensitivity, specificity, and positive and negative predictive values of, respectively 100%, 30%, 89% and 100%.

**Figure 1:** Version 1 of the generic telemedicine platform developed in the E-care telemonitoring project in heart failure patients. This platform utilized nonintrusive medical sensors measuring blood pressure, heart rate, oxygen saturation and weight connected by Bluetooth and relaying real-time physiological data on the health status of the patient; touchscreen tablets connected by Wi-Fi or 3G/4G; and an Internet server hosting an inference engine that generated the warning alerts. These alerts indicated deterioration in the patient's chronic diseases. Health professionals could access them via a secure Internet portal.

**Clinical impact of the French telemedicine projects**

To date, clinical results are only available for SCAD and E-care projects [26,31]. In the SCAD project, 90 patients were randomized from 2009 April to 2011 May (n=45 for each group) (Thesis from the Faculty of Medicine from Caen, France). The population is elderly, with a mean age of 78 ± 6 years, mostly male (78%) and at high risk of re-hospitalization (mean BNP level of 1,025 ± 950 pg/mL). At 12 months, 1,040 days of hospitalization for acute heart failure were recorded. Monitoring by educational telemedicine significantly reduced the number of hospital days for acute heart failure: 590 days in the “control group” vs. 450 days in the “telemedicine group” (p=0.044). The criterion "death or hospitalization for acute heart failure” occurred less frequently in the telemedicine group: 57.8% in the “control group” vs. 35.6% in the “telemedicine group” (p <0.05). During CHF readmissions, telemedicine-treated patients had lower intra-hospital mortality: 18.2% vs. 0% (p <0.02).

Perspectives on new telemedicine projects in France

As discussed above, the E-care platform appears to be capable of preventing hospitalization by detecting any deterioration in the patient's health status early and by making it possible for the care providers in charge of the patient to be warned and, above all, to intervene [30,31]. The E-care platform as others’ currently underway is also capable of structuring the patients’ cares pathways, a major theme in medicine for our governments and authorities (Table 1). It is also capable of providing a means for the various healthcare professionals to exchange with each other; and of facilitating access to medical resources. With this in mind, an enhanced version of the E-care platform will be experimented in the homes of heart failure patients as part of a project called PRADO INCADO (Figure 2) [32].
Telemedicine Projects in other Field of Chronic Diseases

Diabetes

Diabetes and metabolic disorders are other fields of priority investigation of telemedicine in France, outside CHF. Innovative projects are being developed or deployed, such as the PLASIDIA platform, run by the European Center for the Study of Diabetes [35]. It is in this setting, we developed an up graduate version of the E-care platform to follow patients suffered from diabetes mellitus under the DIABETe project. The new version of the E-care platform should be deployed in “complex diabetic” patients; e.g. diabetic patients with high cardiovascular risk or diabetic patients treated with multiple injections [36]. The objective of the DIABETe project is to detect early the risk of hospitalization of diabetic patients with a very high cardiovascular risk: personal history of stroke, IDM, amputation and cardiomyopathy, with intensive insulin therapy (minimum of 3 injections per day or pump), through a personalized follow-up and accompany the patient in the knowledge of his illness and his management. This population is interesting because it allows targeting poly-pathology and poly-medication. It requires global support. It represents 50% of diabetics hospitalized in departments of Diabetology and Internal Medicine. Apart from cardiovascular complications (IDM, PAO, etc.), they are also hospitalized for hypoglycemia, imbalance of diabetes, iatrogenic, infections, etc. The DIABETe project is based on an intelligent platform that will assist the medical profession by automating the processing of information from non-intrusive medical sensors (blood glucose meter, blood pressure monitor, actimeter, connected scale, etc.) as well as subjective information from the patient himself (questionnaires) and its behavior (compliance) to detect and report these situations at risk of hospitalization early. Therapeutic education tools adapted to the patient and the situation will be made available to the individual. Communication to the subject will be provided by a touch pad. Alerts testifying to a deterioration of the patient’s condition will be generated by AI and reported to health professionals in charge of the patient, to anticipate the decompensation and to afford the means of care outside the emergency setting. These solutions, derived from new technologies, will be innovative and original to offer the best acceptability by patients. It will allow the sharing of medical data between health professionals as part of a city-hospital network. Ultimately, it should also lead to an improvement in the quality of life of the patient.

DIABETe does not compete with Diabeo or other expert systems whose purpose is to optimize the glycemic balance, which in itself is one of the essential objectives of diabetes mellitus [37]. The DIABETe project aims at “global” management of the diabetic patient through the detection of situations at risk of hospitalization: infection, cardiac decompensation, diabetic foot, etc. but also of course hypoglycemia and hyperglycemia leading to hospitalizations. It should also be noted that the remote monitoring platform used in DIABETe is likely to integrate or interface with expert systems such as Diabeo. As a reminder, the Diabeo application, carried by SANOFI, was tested as part of the Télésage clinical trial for 700 patients with DT1 and DT2, under a basal bolus regimen (multi-injection or pump) [28]. The main criterion of the Télésage study is the variation of HbA1c (glycemic control) at one year. A previous study, Télédia1b, conducted between 2007.

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is another field of interest of telemedicine. In fact, remote in-home monitoring of symptoms and physiological variables may allow early detection and treatment of exacerbations of COPD. However to date, it is unclear whether telemonitoring improves patient outcomes or healthcare resource utilization. Several “proofs of concept” studies were fairly inconclusive regarding any potential clinical benefit in terms of, for
instance, re-hospitalization or a decrease in morbidity and mortality [38-39]. Two randomized trials and several assessments of remote surveillance were included (for review see the reference [39]). Generally, the studies were low-power, had heterogeneous populations, and showed a lack of detailed descriptions of interventions and care management processes accompanying telemonitoring. There were results in terms of measurement but no economic evaluation. Remote monitoring interventions differed widely in each study. Some contained an educational element that could explain the differences between the groups. Despite these reservations, the study reports seem to be positive. From the literature, the best telemonitoring outcomes come from programs dedicated to aged and very sick patients, frequent exacerbators with multi-morbidity and limited community support; programs using 2.0 or 3.0 telemonitoring systems providing constant analytical and decision making support (24 h/day, 7 days/week); countries where strong community links are not available; and zones where telemonitoring and analytical monitoring can be delivered directly to the patient’s location (for review see the reference [39]). In regard of the published results, the key to optimizing the use of telemonitoring in COPD is to correctly identify who the ideal candidates are, at what time they need it, and for how long. The time course of disease progression varies from patient to patient; hence identifying for each patient a ‘correct window’ for initiating telemonitoring could be the correct solution.

Conclusion

Although many telemedicine projects have been conducted in the CHF area, relatively few have been conducted in the setting of telemedicine 2.0 with aid of ICT and the Internet. The E-care telemonitoring project is one that wholly falls under this category. Their potential utility in terms of morbidity, mortality and avoidance of hospital admissions is being studied or documented. Their impact in terms of health savings is also being assessed. The telemedicine 2.0 projects are perfectly compatible with the care pathways being developed in chronic diseases by the French health authorities (including the French ministry of health and the regional branch of the national health insurance). What’s more, all these findings should be analyzed with regard to the benefit of these telemedicine solutions (Table 1). This experience may lead us to witness the birth of the medicine of tomorrow. In the field of chronic diseases, given the epidemiology and expected shortage of time careers can provide, what we need is better follow-up and better education, improved prevention and anticipation, but, above all, better selection of the patients whose use of the healthcare system will be indispensable.

Declaration

Competing Interests: M. Hajjam is the scientific Director of PREDIMED Technology.
Funding: None declared.
Ethical approval: Not applicable.

Guarantor: EA.
Contributor ship: EA and ST designed the study and conducted the searches. EA, ST and AH composed the results and parts of the discussion. ST, MH and AH provided critical analysis and revising of all portions of the manuscript and authorised the final version for publication. EA is responsible for all revisions and maintains contact with the rest of the review team with status reports.

Acknowledgements


References


27. http://www.osicat.fr/


35. https://www.predimed-technology.fr/


